Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation Implications for Bleeding Risk and Prognosis by Ruiz-Nodar, Juan M. et al.
A
m
w
F
A
A
S
H
2
Journal of the American College of Cardiology Vol. 51, No. 8, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
PFOCUS ISSUE: ATRIAL FIBRILLATION
Anticoagulant and Antiplatelet
Therapy Use in 426 Patients With
Atrial Fibrillation Undergoing Percutaneous
Coronary Intervention and Stent Implantation
Implications for Bleeding Risk and Prognosis
Juan M. Ruiz-Nodar, MD, PHD,* Francisco Marı´n, MD, PHD,†‡ José Antonio Hurtado, MD,†‡
José Valencia, MD, PHD,* Eduardo Pinar, MD, PHD,†‡ Javier Pineda, MD, PHD,*
Juan Ramo´n Gimeno, MD, PHD,†‡ Francisco Sogorb, MD, PHD,* Mariano Valdés, MD, PHD,†
Gregory Y. H. Lip, MD, FACC, FESC§
Alicante, Murcia, and Madrid, Spain; and Birmingham, United Kingdom
Objectives This study was designed to review outcomes in relation to antithrombotic therapy management strategies for
patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stenting.
Background There is limited evidence on the optimal antithrombotic therapy management strategies for patients with AF
who undergo PCI with stenting.
Methods We reviewed 426 patients (70.9% men, mean age 71.5 8.5 years) with AF undergoing PCI with stenting between
2001 and 2006. We recorded clinical and demographic characteristics of the patients, stroke risk factors, and anti-
thrombotic therapy use before PCI and at discharge. Clinical follow-up was performed, and all bleeding episodes,
thromboembolism, and major adverse cardiac events (MACE) (i.e., death, acute myocardial infarction, or target lesion
revascularization) were recorded.
Results The most commonly associated comorbidities were hypertension (74.5%), diabetes mellitus (40.2%), chronic renal
failure (14.9%), and congestive heart failure (26.7%); 80% of patients had2 stroke risk factors. Of the drugs pre-
scribed at discharge, aspirin plus clopidogrel were used in 174 patients (40.8%), whereas 213 patients (50%) were
discharged with triple therapy (coumarins, aspirin, and clopidogrel). Complete follow-up was achieved in 87.5% (me-
dian 594 days; range 0 to 2,190). The incidence of adverse events was high (36.6%), with major bleeding in 12.3%,
thromboembolic events in 4.2%, and MACE in 32.3%. All-cause mortality was high (22.6%). In a multivariate analysis,
non-anticoagulation with coumarins increased mortality (17.8% vs. 27.8%; hazard ratio [HR] 3.43; 95% confidence
interval [CI] 1.61 to 7.54; p  0.002) and MACE (26.5% vs. 38.7%; HR 4.9; 95% CI 2.17 to 11.1; p  0.01) In a
Cox-regression analysis, non-anticoagulation (p 0.01) and age (p  0.02) were independent predictors of MACE.
Conclusions Patients with AF undergoing PCI with stenting represent a high-risk population because of age, comorbidities, and
presence of stroke risk factors. These patients have a high mortality and MACE rate, which is reduced by anticoagula-
tion therapy. (J Am Coll Cardiol 2008;51:818–25) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.035a
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itrial fibrillation (AF) is the most common cardiac arrhyth-
ia and its association with stroke and thromboembolism is
ell recognized. In high-risk patients with nonvalvular AF,
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007, accepted November 20, 2007.nticoagulation with coumarins is recommended to re-
uce the risk of stroke and thromboembolic events (1). In
atients with stable coronary artery disease, treatment
ith aspirin or clopidogrel is recommended for cardio-
ascular prevention (2), whereas dual antiplatelet therapy
ith aspirin plus clopidogrel is advised following presen-
ation with an acute coronary syndrome (ACS) or fol-
owing coronary artery stent deployment (3,4). The
ecommended duration of dual antiplatelet therapy var-
es, ranging from 4 weeks following bare-metal stent
mplantation during elective angioplasty to at least 6 to
2 months with drug-eluting stents (DES), in view of the
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February 26, 2008:818–25 Anticoagulation in AF Patients Undergoing Stentingisk of late stent thrombosis, and for 12 months following
presentation with ACS (4–6).
A management problem arises when a patient in whom
ong-term anticoagulation with coumarins is recom-
ended as thromboprophylaxis because AF subsequently
resents with ACS and/or undergoes percutaneous cor-
nary intervention (PCI) and/or stenting. Coumarin
onotherapy is a poor therapeutic choice in post-stent
atients, with a high rate of adverse cardiac complications
fter stent implantation (7). However, anticoagulation with
oumarins in coronary artery disease subjects may provide a
imilar degree of “vascular protection” to antiplatelet ther-
py, at least in the post-ACS setting (8). In contrast, the use
f “aspirin plus coumarins” or “triple therapy” (aspirin,
lopidogrel, and coumarins) is associated with more bleed-
ng complications (8,9).
A delicate balance between risk of recurrent cardiac
schemia (either post-ACS or from stent thrombosis),
troke/thromboembolic complications, and the risk of major
leeding is therefore needed. Unfortunately, there is a lack
f published evidence on the optimal antithrombotic man-
gement strategy in anticoagulated AF patients who present
ith an ACS and/or undergo PCI/stenting and hence
equire antiplatelet therapy. The 2006 American College of
ardiology/American Heart Association/European Society
f Cardiology guidelines on AF management (10) acknowl-
dge that no adequate studies specifically address this issue
n patients who also require chronic anticoagulation because
f AF and suggest that the maintenance regimen should be
combination of clopidogrel and coumarins for 9 to 12
onths, after which warfarin may be continued as mono-
herapy in the absence of a subsequent coronary event
10). Other authorities (11) have suggested an antithrom-
otic management schema based on ACS presentation,
erceived bleeding risk, and the type of stent used. None
f these strategies have been tested in prospective ran-
omized trials.
Given that randomized trials are unlikely to provide the
nswer in the short term, registry data may give some
nsight into the important management question. In this
rticle, our objective was to present a case series of 426
atients with AF undergoing PCI with stenting from
egistry data available from 2 teaching hospitals, with
articular attention to clinical and demographic character-
stics of the patients, stroke risk factors, and antithrombotic
herapy use before PCI and at discharge, as well as bleeding,
hromboembolism, and major adverse cardiac events
MACE) (i.e., death, acute myocardial infarction, target
esion revascularization) at follow-up.
ethods
e conducted a retrospective 2-center registry analysis
ased on a search of our computerized PCI/stenting data-
ase of those patients diagnosed with AF that underwent
CI with at least 1 stent implanted over a 5-year period aJanuary 2001 to December
006); all of the outcome data
ere collected post hoc. We in-
luded patients from Hospital
eneral Universitario of Ali-
ante, which is a teaching hospi-
al serving a population of ap-
roximately 800,000 that has 5
nterventional cardiologists and
erforms 1,300 PCI procedures a
ear. The second hospital was
ospital Virgen de la Arricaca,
urcia, which has 7 interven-
ional cardiologists serving a
opulation of 1,100,000 and performs 1,400 PCI proce-
ures a year. We recorded clinical and demographic char-
cteristics of the patients, stroke risk factors, and antithrom-
otic therapy use before PCI and at discharge. Stroke risk of
ur patients was assessed by the CHADS2 (1 point each for
he presence of Congestive heart failure, Hypertension, Age
5 years or older, and Diabetes mellitus and by assigning 2
oints for history of Stroke or transient ischemic attack)
core (12). Clinical follow-up was performed, and all bleed-
ng episodes, thromboembolism, and MACE were re-
orded.
Patients with a preexisting diagnosis of permanent, per-
istent, or paroxysmal AF and those who developed new-
nset AF during their current admission were included in
his analysis. The type of stent implanted was recorded, and,
ince May 2002, DES were routinely available for use in both
ur hospitals. Individual patient management decisions, such
s the type of revascularization performed or the type of stent
mplanted, were decided by the interventional cardiologist
nd/or the responsible cardiologist. The regimen of oral
nticoagulation and/or antiplatelet drugs at discharge was
gain decided by the responsible clinical cardiologist on the
asis of type of AF, stroke/thromboembolic risk factors,
omorbidities, revascularization procedure, and the type of
tent used.
At discharge, patients were followed up as part of the
sual routine for each center. Telephone follow-up was
lso performed to confirm the antithrombotic therapy
egimen followed after discharge, as well as to ascertain
ny episodes of bleeding, stroke/thromboembolism,
nd/or MACE. Clinical records of patients with hospital
eadmissions and/or outpatient clinic interviews were also
eviewed for further information to validate our registry
atabase.
nd point definitions. For the follow-up analysis, the
rimary end point was defined as the occurrence of MACE
pisodes, including death, MI, or target vessel revascular-
zation. A secondary safety end point was major adverse
vents (MAE), which included the occurrence of any
ACE, major bleeding complications, and/or stroke dur-
ng the follow-up period. Myocardial infarction was defined
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AF  atrial fibrillation
DES  drug-eluting stent(s)
MACE  major adverse
cardiac events
MAE  major adverse
events
PCI  percutaneous
coronary interventions either the development of pathologic Q waves in at least
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Anticoagulation in AF Patients Undergoing Stenting February 26, 2008:818–25contiguous leads with an elevated creatine kinase-MB
raction level or, in the absence of pathologic Q waves, an
levation in creatine kinase-MB levels to more than twice
pper limit of normal. Major bleeding was defined as a
ecrease in the blood hemoglobin level of more than 5.0
/dl (including the period around the coronary interven-
ional procedure), the need for the transfusion of 2 or more
nits of blood, the need for corrective surgery, the occur-
ence of an intracranial or retroperitoneal hemorrhage, or
ny combination of these events (13).
tatistical analysis. Continuous variables were tested for
ormal distribution by the Kolmogorov-Smirnov test. The
ormal distributed continuous variables are shown as mean 
D, and those nonparametrically distributed are shown as
edian (interquartile range). Discrete variables are presented as
requencies (percentages). The comparison of discrete variables
as done via the chi-square test or (when the 2  2 table had
5 patients) the Fisher test. Comparisons of the groups for
ontinuous variables were performed with the unpaired t test
or independent samples that were parametrically distributed;
or nonparametric variables, the Mann-Whitney U test was
sed.
Survival analyses were initially conducted using a Kaplan-
eier analysis and compared by the log-rank test. Second,
e performed a stepwise Cox proportional hazard model
nalysis, considering the presence of any event as an end
oint and introducing influencing variables as age, type of
F, different cardiovascular risk factors (e.g., hypertension,
iabetes, heart failure, and so on), use of DES, diameter and
otal length of stent, and antithrombotic therapy at
Baseline Characteristics of the Study Populatio
Table 1 Baseline Characteristics of the Stu
Whole C
n  4
Men, n (%) 70.
Age (yrs) 71.5
Medical history
Diabetes (%) 40.
Hypertension (%) 74.
Previous heart failure (%) 26.
Previous stroke or thromboembolism (%) 15.
Renal failure 14.
Number of embolic factors 2.5
Any embolic factor 95.
CHADS2 risk score 2 (1
Previous ischemic events (%) 43.
Treatment on admission (%)
Previous aspirin 36.
Previous clopidogrel 13.
Previous oral anticoagulation 50.
Indication of the catheterization procedure (%)
Acute STEMI 20.
Acute NSTEMI 63.
Stable angina and/or ischemia 16.
CHADS2 is an acronym for stroke risk factors (Congestive heart failu
transient ischemic attack, score  2) and their scoring (a score of 2
comparison of the chronic AF versus paroxysmal AF groups.
AF  atrial fibrillation; NSTEMI  non–ST-segment elevation myocardial inischarge. In the multivariate model, we also included
hose variables that showed a p value 0.15 in the
nivariate analysis when comparing patients with and
ithout oral anticoagulation at discharge. All p values
ere 2-sided, and a p value of 0.05 was considered
tatistically significant.
esults
e reviewed 426 patients (70.9% men, mean age 71.5  8.5
ears) with AF undergoing PCI with stents between 2001 and
006. Of the 426 patients, 256 (60.1%) had permanent AF and
70 (39.9%) had paroxysmal AF (Table 1). The population
as older, with diabetes mellitus in 40%, hypertension in
4.5%, heart failure or impaired cardiac function in 47%, and
revious coronary events in 44%. There was at least 1 risk
actor for stroke/thromboembolism in 96% of the patients, and
0% had 2 stroke risk factors. Specifically, 93% of the
atients had a CHADS2 score of 1, whereas 69% had a
HADS2 score of2. At least 1 DES was used in 40% of the
atients, and complete revascularization was only achieved in
0% (Table 2).
ntithrombotic drug regimen at discharge. Of the drugs
rescribed at discharge, dual antiplatelet therapy (aspirin
lus clopidogrel) was prescribed in 174 (40.8%), whereas
13 (50.0%) were discharged with triple therapy (couma-
ins, aspirin, and clopidogrel). Furthermore, 15 patients
3.6%) were receiving a single antiplatelet drug, whereas
4 (5.6%) were taking coumarins plus 1 antiplatelet drug
Table 3). There was wide variability in the antithrom-
pulation
Chronic
n  256 (60.1%)
Paroxysmal
n  170 (39.9%) p Value
69.0 73.7 0.31
72.3 8.5 70.0 8.5 0.01
41.5 38.2 0.49
75.4 73 0.58
32.4 17.4 0.01
18 12.4 0.14
12.8 21.4 0.39
2.7 1 1.9 1.1 0.01
96.9 92.3 0.21
2 (2–3) 2 (1–2) 0.01
45.1 40.3 0.29
31.5 43.6 0.01
13.4 14.5 0.77
69.2 16.0 0.01
0.22
16.4 25.7
66.1 60.5
17.5 13.8
ertension, Age 75 years, Diabetes, all with a score  1; Stroke or
es “high risk” for stroke and thromboembolism). p values are for then
dy Po
ohort
26
9
8.5
2
5
7
9
9
1.1
8
–3)
7
2
8
1
1
8
1
re, Hyp
indicatfarction; STEMI  ST-segment elevation myocardial infarction.
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February 26, 2008:818–25 Anticoagulation in AF Patients Undergoing Stentingotic therapy regimen and duration of treatment used by
he 2 hospitals and between the interventional cardiologists.
f the patients discharged with triple therapy, there was no
onsistency in the duration of treatment, with either coumarins
r 1 antiplatelet agent being stopped at 1 month following PCI
here bare-metal stents were used and between 3 and 12
onths when a DES was used. Ticlopidine was used in a very
mall number of patients (n  13), and thus, numbers were
ncluded within the clopidogrel group.
In the patients with permanent AF, the antithrombotic
rug regimen most commonly used was triple therapy
55.8%), in comparison with patients with paroxysmal
F, where dual antiplatelet therapy predominated
49.5%). Characteristics of the population treated with
oumarins at discharge in relation to those not treated
ith such drugs are shown in Table 4. Those discharged
aking coumarins were a higher risk population, given the
igher proportion of hypertension and previous embolism
nd a higher number of stroke/thromboembolism risk
actors.
ollow-up analysis. Complete follow-up was achieved in
8% of the cohort (median 595 days; range 0 to 2,190
ays). The incidence of adverse events was high (35%),
ith major bleeding in 12.3%, thromboembolic events in
.2%, and MACE in 32.3% (Table 5). All-cause mortal-
ty was also high (22.6%). In a multivariate Cox regres-
ion analysis, nonanticoagulation with coumarins signif-
cantly increased mortality (17.8% vs. 27.8%; hazard ratio
Procedural Characteristics
Table 2 Procedural Characteristics
Whole Coh
n  426
Left ventricular ejection fraction 45% 31.2%
Stent diameter used (mm) 2.9 0.
Total stent length (mm) 29.7 21
No. of total stents 1.8 1.
Patients with DES (%) 40.1
No. of total DES in patients with DES 1.9 1.
Complete revascularization 60.2
Glycoprotein IIb/IIIa inhibitor 25.7
p values are for the comparison of the chronic AF versus paroxysmal
DES  drug-eluting stent; other abbreviations as in Table 1.
Antithrombotic Regimen Adopted in AF Patients
Table 3 Antithrombotic Regimen Adopted in
Whole Coh
n  426
Coumarin  aspirin  clopidogrel (%) 213 (50)
Aspirin  clopidogrel (%) 174 (40.8
Coumarin  aspirin (%) 8 (1.9)
Coumarin  clopidogrel (%) 16 (3.7)
Coumarin monotherapy (%) 5 (1.2)
Aspirin monotherapy (%) 5 (1.2)
Clopidogrel monotherapy (%) 5 (1.2)The p value is for the comparison of the chronic AF versus paroxysmal AF groHR]  3.43; 95% confidence interval [CI] 1.61 to 7.54;
 0.002) and MACE (26.5% vs. 38.7%; HR  4.9;
5% CI 2.17 to 11.1; p  0.001).
Among the patients who were prescribed oral antico-
gulants at discharge, there was a nonsignificant increase
n major bleeding (14.9% vs. 9.0%; p  0.19) (Fig. 1A)
log-rank test p  0.64) but a significantly better
ACE-free prognosis (Fig. 1B) (log-rank test p  0.02),
s well as a lower all-cause mortality (Fig. 1C) (log-rank
est p  0.02). In a Cox regression analysis, nontreatment
ith coumarins at discharge (p  0.001) and age (p 
.017) were independent predictors of MACE (Table 6).
For the secondary safety end point (MAE) that in-
luded the occurrence of any MACE, major bleeding
omplications, and/or stroke at follow-up, this end point
as lower among those patients treated with coumarins
26.8% vs. 39.2%; p  0.014). In a Cox regression
nalysis, age (p  0.019) and nontreatment with couma-
ins at discharge (p  0.001) were independent predictors
f MAE (Table 7). There was no significant increase in
he incidence of major hemorrhagic events in the patients
reated with coumarins.
Acute coronary syndromes (non–ST-segment elevation
n 63.8%, ST-segment elevation in 20.1%) were the main
ndication for the PCI procedure, but this did not have any
nfluence on either the type of treatment at discharge or the
ong-term prognosis (Table 4).
Chronic
n  256
Paroxysmal
n  170 p Value
31.3% 30.8% 1.0
2.9 0.5 2.9 0.5 0.61
27.6 17.0 32.9 27.2 0.03
1.7 0.9 2.1 1.5 0.01
40.7 39.2 0.75
1.6 0.9 2.3 1.5 0.01
56.3 66.7 0.04
20.4 34.3 0.01
ps.
ischarge
atients at Discharge
Chronic
n  256
Paroxysmal
n  170 p Value
143 (55.8) 70 (41.3)
90 (35.2) 84 (49.5)
6 (2.3) 2 (1.2)
13 (5.1) 3 (1.7)
2 (0.8) 3 (1.7)
0 5 (2.9)
2 (0.8) 3 (1.7)
0.01ort
5
.9
2
2at D
AF P
ort
)ups (Fisher test p  0.01).
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Anticoagulation in AF Patients Undergoing Stenting February 26, 2008:818–25ES subgroup. Of the whole cohort, 174 patients (40.1%)
ere treated with at least 1 DES. A higher prevalence of
iabetes mellitus was observed in those patients treated with
ES (46% vs. 35%: p  0.03), but no other differences in
linical characteristics were observed. The number of stents
mplanted in the DES group was higher (2.17 vs. 1.59; p 
.01), smaller (2.78 mm vs. 2.99 mm; p 0.01), and longer
39 mm vs. 35 mm; p  0.01). In a univariate analysis, a
ower incidence of MACE was observed in the DES group
29.0% vs. 40.5%; p  0.032); however, this difference did
ot persist in a multivariate analysis. Patients treated with
ES had a higher rate of stent thrombosis (2.8% vs. 0%;
 0.034).
Differences Between the AF Patients Undergoinscharg With Anticoagulation Compared to ThAnticoa ulat on
Table 4
Differences Between the AF Patien
Discharge With Anticoagulation Co
Anticoagulation
Whole Cohort
n  426
Men (%) 70.5
Age (yrs) 71.5 8.5
Diabetes (%) 40.2
Hypertension (%) 74.5
Previous heart failure (%) 26.7
Previous stroke (%) 15.9
Renal failure 14.9
No. of embolic factors 2.5 1.1
Any embolic factor 95.8
CHADS2 risk score, median (IQR) 2 (1–3)
Previous ischemic events (%) 43.7
Treatment on admission (%)
Previous aspirin 36.2
Previous clopidogrel 13.8
Previous oral anticoagulation 50.1
Indication of the catheterization
procedure (%)
Acute STEMI 20.1
Acute NSTEMI 63.8
Stable angina and/or ischemia 16.1
The p values are for the comparison of the “anticoagulated” versus “n
IQR  interquartile range; PCI  percutaneous coronary interventio
Events During Follow-Up
Table 5 Events During Follow-Up
Whole Cohort
n  373
Major bleeding (%) 12.3
Minor bleeding (%) 11.0
Embolism (%) 4.2
Death (%) 22.6
Acute myocardial infarction (%) 8.4
Target vessel revascularization (%) 7.7
Target vessel failure (%) 9.2
Revascularization of other lesions (%) 7.1
Subacute or late thrombosis (%) 1.2
MACE (%) 32.3
MAE (%) 36.6The p value represents the comparison of the anticoagulated and nonanticoa
MACE  major adverse cardiovascular events; MAE  major adverse eveniscussion
o our knowledge, this is the largest dataset of AF patients
ndergoing PCI/stenting where antithrombotic therapy
anagement strategies have been related to clinical out-
omes. We show that our patients with AF undergoing PCI
ith stenting represent a high-risk population owing to age,
omorbidities, and the presence of stroke risk factors, as well
s the relatively high incidence of acute coronary syndromes
s the indication for PCI. We show a lack of any coordi-
ated strategy for the prevention of thrombotic or throm-
oembolic events in this AF population, with a high
ortality rate and MACE. Importantly, our data confirm
I/Stenting, Treated atNot Treated With
dergoing PCI/Stenting, Treated at
d to Those Not Treated With
nticoagulated
n  242
Not Anticoagulated
n  184 p Value
70.7 70.4 0.93
71.6 8.7 71.2 8.5 0.74
42.5 41.8 0.91
81.6 72.1 0.04
29.2 22.8 0.18
19.6 11.1 0.04
10.9 22.9 0.09
2.8 1.0 2.2 1.1 0.01
98.8 90.6 0.04
2 (1–3) 2 (1–3) 0.02
43.2 44 0.99
30.3 40.9 0.05
11.0 17.8 0.11
69.2 27.7 0.01
0.20
16.0 23.1
66.0 61.3
18.6 15.6
oagulated” groups.
r abbreviations as in Table 1.
Anticoagulated
n  195
Not Anticoagulated
n  178 p Value
14.9 9.0 0.19
12.6 9.0 0.32
1.7 6.9 0.02
17.8 27.8 0.02
6.5 10.4 0.14
7.1 8.4 0.3
9.2 16.7 0.01
5.9 8.5 0.25
1.2 1.3 0.65
26.5 38.7 0.01
31.8 41.9 0.03g PCose
ts Un
mpare
Agulated groups.
ts.
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February 26, 2008:818–25 Anticoagulation in AF Patients Undergoing Stentinghe protective effect of the coumarins in patients with AF
reated with PCI/stents by decreasing the incidence of
ACE. In addition, the beneficial effect of coumarins is
onfirmed in the multiple regression analysis, where age and
ontreatment with coumarins were the only independent
redictors of MACE. On the basis of these data, we
onsider that in those patients with AF treated with
CI/stents who have a low risk of bleeding complications, a
riple-therapy regimen should be the elective antithrom-
otic drug treatment approach.
The present study also illustrates that various antithrom-
otic drug combinations are used in everyday practice. Such
ariability is understandable in light of the lack of available
uidelines. Indeed, the post-PCI strategy should be tailored
o the individual patient and their risk of thromboembolism
nd stent thrombosis against their risk of bleeding while
eceiving triple therapy (14). In the small case series by Lip
nd Karpha (11), for example, 35 patients were reviewed
ver a 5-year period, but the study did illustrate the wide
ariability in management strategies between interventional
ardiologists.
The combination of coumarins plus aspirin after PCI has
reviously been shown to be less effective compared to
iclopidine plus aspirin in preventing stent thrombosis
7,15,16). Of note, 1 stroke prevention trial in AF had to be
topped early because of the clear superiority of oral anti-
oagulation over dual antiplatelet therapy with aspirin plus
lopidogrel (17). This may explain why triple therapy has
een commonly used in this series, as well as in other case
eries (18), despite the lack of data from clinical trials.
owever, such combination therapy increases the risk of
leeding (9,18,19). Our series also highlights the variability
n the use of anticoagulant/antiplatelet therapy in patients
ndergoing PCI with stenting who have AF. Although the
ombination of aspirin and clopidogrel (40.7%) or triple
herapy (50.0%) accounted for the majority of patients, the
uration of their use still varied widely among patients. This
ariability was due essentially to the use of DES, in which
ustained therapy with clopidogrel between 6 and 12
onths was recommended, as opposed to patients treated
ith bare-metal stents, in which clopidogrel was maintained
or only 1 month.
A recent meta-analysis with estimates of risk and
enefit of coumarins plus aspirin after myocardial infarc-
ion of ACS reviewed 10 trials involving a total of 5,938
atients and concluded that for patients who are at low or
ntermediate risk for bleeding, the cardiovascular benefits
f coumarins outweigh the bleeding risks (20). The data
rom Karjalainen et al. (18) support the view that triple
herapy is currently the best option for the majority of the
atients, although this predisposes to an increased risk of
leeding, which may require stopping anticoagulation
nd/or antiplatelet therapy. Such therapy cessation ex-
oses these patients to stent thrombosis or stroke/Figure 1 Kaplan-Meier Survival Curves in
Relation to Anticoagulation Use at Discharge
Patients were stratified according to anticoagulation use at discharge com-
pared to non-use. (A) Major bleeding: log-rank test, p  0.6; (B) major
adverse cardiovascular events: log-rank test, p  0.02; and (C) all-cause mor-
tality: log-rank test, p  0.03. Number of patients followed: anticoagulation
group, n  195; no-anticoagulation group, n  178. Dotted lines  no antico-
agulation use at discharge; solid lines  anticoagulation use at discharge.hromboembolism. Other series quantify the use of triple
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ajor bleeding risk (19).
In the present series, DES were used in 40.1% of the
atients and more frequently in diabetic patients. The type
f antithrombotic therapy used in DES patients at discharge
as generally similar to that of the patients treated with
are-metal stents, with the exception of the duration of
lopidogrel. In a multivariate analysis, there was no signif-
cant difference in the incidence of MACE when DES was
sed. It should also be emphasized that patients treated with
ES had a higher rate of stent thrombosis (2.8% vs. 0%;
 0.034), although this finding should be interpreted with
aution given the smaller subgroup here, to evaluate an end
oint with such a low incidence. However, the implantation
f DES should probably be discouraged in anticoagulated
F patients owing to the need for prolonged dual antiplate-
et administration (21,22).
This large study is limited by its registry design. This was
ot a randomized controlled trial, and many confounders/
iases are possible, although we have tried to address most
n a multivariate analysis. Another limitation is the changes
Cox Regression for the Analysis of Major Advers
Table 6 Cox Regression for the Analysis of
Variables 
Age 0.06
Type of AF 0.41
Hypertension 0.36
Diabetes 0.23
Congestive heart failure or low LVEF 0.15
Renal failure 0.89
Previous stroke 0.22
Previous aspirin 0.23
Previous clopidogrel 0.13
Previous oral anticoagulation 0.76
Use of DES 0.35
Nonanticoagulation at discharge 1.59
Complete revascularization 0.68
AF  atrial fibrillation; CI  confidence interval; DES  drug-eluting s
Cox Regression Analysis for Major Adverse Even
Table 7 Cox Regression Analysis for Major
Variables 
Age 0.06
Type of AF 0.47
Hypertension 0.29
Diabetes 0.23
Congestive heart failure or low LVEF 0.13
Renal failure 0.87
Previous stroke 0.28
Previous aspirin 0.12
Previous clopidogrel 0.08
Previous oral anticoagulation 0.78
Use of DES 0.39
Nonanticoagulation at discharge 1.47
Complete revascularization 0.56Abbreviations as in Table 6.f antithrombotic regiment in these patients during the
ollow-up period, sometimes in relation to the presence of
hrombotic or hemorrhagic complications. Although lim-
ted by the experience of 2 European centers, this large
eries still clearly reveals the complexity, high comorbidity,
nd high risk of the population with AF that has undergone
CI/stenting, as well as the lack of any coordinated strategy
n the prevention of stroke/thromboembolic events among
nticoagulated AF patients. Treatment with coumarins at
ischarge shows a beneficial effect on prognosis by reducing
he incidence of death andMACE, and such benefits do not
ppear to be associated with a substantial increase in major
leeding events. Further large studies are required to assess
he bleeding and thrombotic risk with various post-PCI
trategies in patients with AF to facilitate the development
f guidelines.
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